Stephanie oversees the development of therapies across neuromuscular disorders, neurodevelopmental disorders, and other rare neurological conditions. She brings over 15 years of experience across Research and Development, including roles in Safety, Regulatory, and Clinical Development. Steph has led programs spanning the full development continuum, from early-stage research through marketed therapies. The first approved therapies for SMA, SOD1-ALS, and FA have transformed the therapeutic landscape and helped advance the science and optimal approach to drug development. Reflecting her long-standing leadership in neuromuscular drug development, she also serves as co-chair of the Accelerating Medicines Partnership (AMP) for ALS, a precompetitive public–private collaboration uniting NIH, C‑PATH, FDA, academia, patient advocacy organizations, and industry to accelerate the development of effective ALS therapies.
